Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inad...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Brazilian Society of Endocrinology and Metabolism
2017-02-01
|
| Series: | Archives of Endocrinology and Metabolism |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188&lng=en&tlng=en |
| _version_ | 1819163760346005504 |
|---|---|
| author | Miriam Méndez-del Villar Esperanza Martínez-Abundis Rafael O. Preciado-Márquez Manuel González-Ortiz |
| author_facet | Miriam Méndez-del Villar Esperanza Martínez-Abundis Rafael O. Preciado-Márquez Manuel González-Ortiz |
| author_sort | Miriam Méndez-del Villar |
| collection | DOAJ |
| description | ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control. |
| first_indexed | 2024-12-22T17:49:15Z |
| format | Article |
| id | doaj.art-63af5d2ddc5a43b9a90e396b907ba9ab |
| institution | Directory Open Access Journal |
| issn | 2359-4292 |
| language | English |
| last_indexed | 2024-12-22T17:49:15Z |
| publishDate | 2017-02-01 |
| publisher | Brazilian Society of Endocrinology and Metabolism |
| record_format | Article |
| series | Archives of Endocrinology and Metabolism |
| spelling | doaj.art-63af5d2ddc5a43b9a90e396b907ba9ab2022-12-21T18:18:13ZengBrazilian Society of Endocrinology and MetabolismArchives of Endocrinology and Metabolism2359-42922017-02-0161218819210.1590/2359-3997000000242S2359-39972017000200188Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlMiriam Méndez-del VillarEsperanza Martínez-AbundisRafael O. Preciado-MárquezManuel González-OrtizABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188&lng=en&tlng=enDiacereinmetforminglycemic controltype 2 diabetes mellitus |
| spellingShingle | Miriam Méndez-del Villar Esperanza Martínez-Abundis Rafael O. Preciado-Márquez Manuel González-Ortiz Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control Archives of Endocrinology and Metabolism Diacerein metformin glycemic control type 2 diabetes mellitus |
| title | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| title_full | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| title_fullStr | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| title_full_unstemmed | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| title_short | Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| title_sort | effect of diacerein as an add on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
| topic | Diacerein metformin glycemic control type 2 diabetes mellitus |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188&lng=en&tlng=en |
| work_keys_str_mv | AT miriammendezdelvillar effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT esperanzamartinezabundis effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT rafaelopreciadomarquez effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT manuelgonzalezortiz effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol |